Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy

• Material Type: 博士論文
• ISSN: 0944-1174
• Title: Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy
• Volume: 54 3
• Author/Editor: 鈴木, 裕子
• Publication Date: 2019-03
• Publication Date (W3CDTF): 2019-03
• Alternative Title: 一次化学療法としてゲムシタビン＋シスプラチン併用療法を施行した進行胆道癌の予後因子に関する検討
• Periodical title: Journal of gastroenterology
• Degree grantor/type: 旭川医科大学
• Date Granted: 2019-09-30
• Date Granted (W3CDTF): 2019-09-30
• Dissertation Number: 乙第483号
• Degree Type: 博士（医学）
• Conferring No. (Dissertation): 乙第483号
• Text Language Code: eng
• Subject Heading: Biliary tract cancer; Chemotherapy; Gemcitabine and cisplatin; Prognostic factor; Validation
• Note (General): BACKGROUND: Few studies have clearly identified the prognostic factors in patients with advanced biliary tract cancer (BTC) receiving gemcitabine plus cisplatin (GC) which is acknowledged as standard chemotherapy regimen. OBJECTIVES: The aim of this study was to identify predictive factors of the overall survival (OS) in advanced BTC patients receiving GC therapy. METHODS: Data of 307 patients with advanced BTC who received GC therapy as the first-line chemotherapy at our institution from January 2007 to June 2017 were reviewed retrospectively. The patients were randomly assigned to the investigation or the validation dataset at the ratio of 2:1. Multivariate analysis was conducted to identify the prognostic factors, a prognostic index is proposed from the investigation dataset, and the usefulness of this index was confirmed in the validation dataset. RESULTS: Multivariate analysis identified poor performance status, elevated serum lactate dehydrogenase, and elevated neutrophil-to-lymphocyte ratio as independent unfavorable predictors. The patients could be classified into three groups according to these factors, and it was found that the outcomes differed significantly among the three groups (P = 0.0002, good- vs. intermediate-prognosis groups; P = 0.005, intermediate- vs. poor-prognosis groups). When this index was applied to the validation dataset, the OS was confirmed to differ significantly among the three groups (P = 0.04, good- vs. intermediate-prognosis groups, P < 0.0001, intermediate- vs. poor-prognosis groups). CONCLUSIONS: We identified three predictors of the OS in patients with advanced BTC receiving GC therapy in this study, based on which we could classify the patients into three risk groups.; identifier:PMID：30298469; 開始ページ : 281; 終了ページ : 290
• DOI: info:doi/10.1007/s00535-018-1518-3.; https://doi.org/info:doi/10.1007/s00535-018-1518-3.
• Persistent ID (NDL): info:ndljp/pid/11378233; https://dl.ndl.go.jp/pid/11378233
• Collection: 障害者向け資料
• Collection (Materials For Handicapped People:1): テキストデータ
• Collection (particular): 国立国会図書館デジタルコレクション > デジタル化資料 > 博士論文; https://dl.ndl.go.jp/collections/A00014
• Acquisition Basis: 博士論文（自動収集）
• Date Accepted (W3CDTF): 2019-11-04T14:30:53+09:00
• Format (IMT): application/pdf
• Access Restrictions: 国立国会図書館内限定公開
• Service for the Digitized Contents Transmission Service: 図書館・個人送信対象外
• Availability of remote photoduplication service: 可
• Periodical Title (URI): http://amcor.asahikawa-med.ac.jp/modules/xoonips/detail.php?id=20190930_O483
• Data Provider (Database): 国立国会図書館 : 国立国会図書館デジタルコレクション; https://dl.ndl.go.jp